Clinical trial Recruiting at 1 site Interventional Ages 40 to 85 Men only

TURP versus EchoLaser transperineal laser ablation (TPLA) for men with urinary symptoms from benign prostate obstruction

Official title: Randomized Clinical Trial Comparing Transurethral Prostate Resection (TURP) and Echolaser Soractelite-Transperineal Laser Ablation (TPLA ) in Patients With Lower Urinary Tract Symptoms Due to Benign Prostatic Obstruction

Run by Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari · NCT07289243 · Data updated 2026-11-12

This will test whether EchoLaser transperineal laser ablation (TPLA) works as well as standard TURP to reduce urinary symptoms in men with an enlarged prostate.

Quick facts

Study typeInterventional
Ages40 Years to 85 Years
SexMen only
Enrollment80 (estimated)
SponsorAzienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Academic / other
Locations2 sites (Bari, ITALY/Bari and 1 other locations)
StatusRecruiting
StartedJuly 14, 2024
Main results expectedDecember 25, 2025
Study endsDecember 25, 2026
Registry record updatedSeptember 17, 2026
Trial IDNCT07289243 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adult men with bothersome lower urinary tract symptoms due to benign prostatic obstruction, IPSS ≥8, prostate volume 40–80 mL, and who have not achieved symptom control with medical therapy are the ideal candidates.

Probably not a fit

Patients with prior prostate surgery, indwelling bladder catheters, bladder stones or tumors, active urinary or seminal infections, urethral strictures, or neurologic bladder dysfunction are excluded and unlikely to benefit from enrollment.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized clinical comparison, conducted at Policlinico di Bari, will assign men with lower urinary tract symptoms from benign prostatic obstruction to either standard transurethral resection of the prostate (TURP) or EchoLaser Soractelite transperineal laser ablation (TPLA). Eligible participants have IPSS ≥8, prostate volume 40–80 mL, and have not had successful medical therapy. The primary outcome is non-inferiority of TPLA versus TURP measured by change in IPSS score, with additional outcomes likely to include complications, urinary flow, and recovery metrics. Patients with prior prostate surgery, indwelling catheters, bladder stones or tumors, active infections, urethral strictures, or neurologic bladder dysfunction are excluded.

Why it matters

Potential benefit: If successful, TPLA could offer similar symptom relief to TURP with a less invasive approach and potentially faster recovery or fewer procedure-related complications.

How similar studies have gone: Minimally invasive prostate ablation techniques have shown promising symptom improvements in prior work, and small series of transperineal laser ablation report favorable results, but randomized head-to-head evidence versus TURP remains limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Lower urinary tract symptoms (IPSS \>= 8);
* Poor efficacy after at least six months of medical therapy or intolerance to medical treatment for BPH;
* Prostate volume: 40ml-80ml;
* Ability to give informed consent.

Exclusion Criteria:

* Previous surgery for benign prostatic hyperplasia;
* Indwelling bladder catheter or intermittent bladder catheterization;
* Diagnosis of bladder stones;
* Recurrent urinary tract infections or intraprostatic abscesses;
* Severe detrusor hypocontractility or acontractility;
* Hydronefrosis due to urinary retention;
* Urethral strictures or diagnosis of neurogenic bladder;
* Diagnosis of bladder cancer;
* Diagnosis or clinical suspicion of prostate cancer.

Where it's running

  • UOC Urologia e Trapianti di Rene Policlinico di Bari
    Bari, ITALY/Bari, Italy
    Recruiting
  • UOC Urologia e Trapianti di Rene Policlinico di Bari
    Bari, ITALY/Bari, Italy
    Active not recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.